Patients with chronic hepatitis C virus (HCV) infection have a higher risk of insulin resistance (IR) and type II diabetes mellitus than patients with other liver diseases.
However, it seems that this increased risk of IR is mainly related to HCV infection-related events [1, 2] . One metaanalysis has already shown that pretreatment IR assessment, measured using the homeostasis model assessment of insulin resistance (HOMA-IR), is a major determinant of sustained virological response (SVR) to pegylated-interferon + ribavirin treatment [3] . However, its impact on SVR to telaprevir does not seem significant [4] . The risk of IR and diabetes is even higher in individuals who are coinfected with human immunodeficiency virus (HIV), as a proportion of this population have been exposed to antiretroviral agents (nucleoside/nucleotide reverse transcriptase inhibitors, in particular), which are associated with hyperlipidemia and hypertriglyceridemia [5, 6] .
Cannabis use is widespread in France [7] , particularly by persons with a history of injecting drug use, who represent a large proportion of the HIV-HCV-infected population. Individuals living with HIV often use cannabis for self-medication, as it helps to reduce the burden of symptoms and ensures adherence to antiretroviral treatment [8, 9] . Although cannabis use can increase appetite, it has been associated with a reduced risk of obesity and therefore IR in the general population [10] . Data that reveal the relationship between cannabis use and both diabetes and IR are sparse. However, a recent cross-sectional study, conducted between 2005 and 2010 in the general US population [11] , found that current cannabis use was associated with lower fasting insulin levels and lower risk of IR, highlighted by lower HOMA-IR values and lower risk of diabetes [12] .
We used longitudinal data from the Agence nationale de recherches sur le sida et les hépatites virales (ANRS) CO13 HEP-AVIH cohort of coinfected HIV-HCV patients to test whether cannabis use in this population, which is particularly concerned with both high prevalence of cannabis use and the risk of IR, was consistently associated with a reduced risk of IR.
MATERIALS AND METHODS

Study Design
In 2006, ANRS CO13 HEPAVIH, a multicenter prospective cohort study, was initiated in 21 infectious diseases and internal medicine outpatient clinics that deliver care to HIV-HCV-coinfected patients in France. Consecutive patients attending 21 hospital wards were enrolled according to the following selection criteria: aged ≥18 years; chronically coinfected with HIV and HCV, as confirmed by a positive HIV antibody test and an HCV RNA assay; or spontaneously cured of HCV without HCV treatment or cured after HCV treatment. Provision of written informed consent was also a condition for enrollment [13] .
The institutional review board of Cochin Hospital (Paris) approved the study protocol. The schedule of follow-up visits was based on clinical practice, as recommended by consensus conferences on hepatitis C, ie, every 6 months and every year for cirrhotic and noncirrhotic patients, respectively.
Collection of Biomedical Data
Clinical and biological data, including HIV RNA plasma viral load, CD4 cell count, and degree of liver fibrosis, together with data on HCV treatment initiation, were collected using a clinical research form completed by medical staff in outpatient hospital services. This form also contained other information such as HCV genotype, fibrosis stage, HCV plasma viral load, body mass index (BMI), history of HCV and HIV treatment, fasting glycemia, insulinemia, lipid panel, and comorbidities (such as diabetes, hypertension, cardiovascular problems, renal dysfunction). HIV plasma viral load was considered undetectable if it was below the detection limit (depending on the threshold of the assay used in each outpatient clinic). Although liver biopsy was performed whenever possible at enrollment, a systematic assessment of liver fibrosis was obtained during follow-up using the following 2 noninvasive methods: FibroTest and elastometry by FibroScan. Severe fibrosis (Metavir score F ≥ 3) was assessed using an algorithm that took into account liver biopsy, if available and performed <1 year before the visit; the presence of indirect clinical signs of cirrhosis (esophageal varices, ascites, liver encephalopathy, or digestive bleeding); or results from Fibroscan. The Fibroscan cutoff points used for Metavir score conversion were as follows: F0-F1, <7.1 Kpa; F2, 7.1-9.5 Kpa; F3, 9.5-12.5 Kpa; F4 (cirrhosis), ≥12.5 Kpa [14] .
The HOMA-IR was calculated as fasting insulinemia (µU/ mL) multiplied by fasting glycemia (mmol/L) divided by 22.5. HOMA-IR is generally used to obtain an indicator of insulin resistance in nondiabetic patients [15] . Further details of medical data collection are documented elsewhere [13] .
Patient Self-Administered Questionnaire
The patient self-administered questionnaire was completed at enrollment and during clinical visits every 12 months during the 60 months of follow-up. It detailed sociodemographic characteristics, history of HIV and HCV testing (these 3 only at enrollment), HIV-related symptoms, coffee consumption in the preceding 6 months, and drug (cannabis, heroin, cocaine, crack, ecstasy, street buprenorphine, amphetamines) and alcohol use (AUDIT-C [16] ) in the preceding month.
The frequency of consumption of each drug (cannabis, heroin, cocaine, etc.) in the previous 4 weeks was assessed with the following question: Have you used 1 or more of the following drugs in the previous 4 weeks? Possible answers were "never," "sometimes," "regularly," and "every day." Moreover, in order to minimize social desirability bias, information about regular cannabis use was also recorded using a question about regular smoking (cigarettes or other) and recording answers that indicated regular cannabis smoking. Individuals with missing answers or those classified as nonusers or as occasional users as a result of the answer to the first question about cannabis were reclassified as regular cannabis users if they reported regularly smoking cannabis when they answered the second question.
BMI was also computed from participant size and weight data provided at enrollment.
Statistical Methods
Patient Selection
For the statistical analysis, we selected a subset of patients from the HEPAVIH cohort who attended 1 or more follow-up visits where both HOMA-IR and cannabis use (using the HEPAVIH Cannabis, Insulin Resistance, and HIV-HCV • CID 2015:61 (1 July) • 41 annual self-administered questionnaire) were assessed. All such visits were included in the analysis. Patients with diabetes at enrollment were excluded from the main analysis, as it was possible they had already changed their lifestyles and were receiving different clinical management. For those patients who developed diabetes during follow-up, only visits before diabetes diagnosis were included in the analysis. Furthermore, visits where HOMA-IR assessments were performed after fasting were excluded from the analysis. However, a sensitivity analysis that included patients with diabetes at baseline and visits of those who developed diabetes during follow-up was conducted to verify the robustness of the results.
Outcomes and Correlates
To compare the distribution of included and excluded patients (Table 1 ) and the distribution of patient characteristics as a function of cannabis use at first available data ( Although controversy about which cutoff values to use to define IR remains [17] , we chose a HOMA-IR cutoff value that has already been used in a population without metabolic diseases [18] . This value was also used by Petta et al who found that HOMA-IR >2.7 and platelets <200 × 103/µL were the diagnostic criteria for severe fibrosis (F3 and F4) [19] . The outcome variable was the HOMA-IR measurement, ie, at any given visit, a patient was considered to be at risk of IR if he/she had HOMA-IR values >2.77 at that visit.
To account for the repeated measure design (60-month follow-up) and the presence of fixed (eg, gender) and time-varying correlates, we used a mixed logistic regression model to estimate the adjusted and unadjusted risk of HOMA-IR >2.77 for cannabis use [20] .
The following potential correlates/confounders were taken into consideration to test the relationship between cannabis use and HOMA-IR: (1) HCV genotype, history of HCV treatment and clearance of HCV at enrollment, cirrhosis (elastometry >12.5 Kpa); and (4) consumption behaviors: drug use (any psychotropic drug use, excluding cannabis), tobacco smoking, alcohol use (elevated alcohol consumption), coffee consumption (3 or more cups per day vs fewer than 3 cups), the former figure corresponding to the value found to be beneficial for liver fibrosis [21] , liver enzymes [22] , and response to HCV treatment [23] ). Variables with P values < .20 or known correlates/confounders (eg, coffee consumption) in the univariate analysis were introduced and maintained in the final model if their inclusion significantly improved the model (P < .05 for the likelihood ratio test) or if the variable significantly modified the strength of the association between cannabis use and HOMA-IR.
As some research indicates a link between cannabis use and CD4 cell count [24] , we conducted a mediation analysis to verify whether the relationship between cannabis use and HOMA-IR could have been mediated by CD4 cell count. Accordingly, we tested the relationship between cannabis use and HOMA-IR, cannabis use and CD4 cell count <350, and CD4 cell count <350 and HOMA-IR [25] using the Sobel test [26] . We also conducted 3 sensitivity analyses. For the first 2, HOMA-IR was considered either as a continuous or dichotomous variable, using a cutoff of 3.8, a value associated with the risk of progression to hepatocellular carcinoma in the same cohort [27] . The third sensitivity analysis used HOMA-IR >2.7 as the outcome included patients who had diabetes at enrollment and visits of those who developed diabetes during follow-up.
RESULTS
Descriptive Results
From the cohort's 1324 HIV-HCV-coinfected patients (7035 visits), 66 (5.0%) had diabetes (I or II) at enrollment and were excluded from the analyses. Among the remaining 1258 Table 2) .
Univariate Analysis
Unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the potential correlates of HOMA-IR >2.77 are reported in Table 3 . The univariate analysis (Table 3) showed that cannabis use (whether occasional, regular, or daily) was significantly associated with lower risk of IR. As ORs of any cannabis use category (vs no use) were very similar (Table 3 ) and did not change after multiple adjustments, we decided to collapse the 3 categories of cannabis use. Drinking 3 or more cups of coffee per day was also found to be a significant correlate of reduced risk of IR. Compared with men, women had approximately half the risk of having IR. No significant association was found between HCV genotype and IR (data not shown). Detectable HIV viral load was associated with a reduced risk of IR. All HIV antiretrovirals were tested for, but only exposure to D4T was significantly associated with an increased risk of IR.
Individuals with cirrhosis had at least a 50% higher risk of having IR.
In the mediation analyses, the Sobel test was not significant, thereby confirming no significant mediation effect by CD4 cell count in the relationship between cannabis use and HOMA-IR.
Multivariate Analysis
The relationship between cannabis use and reduced risk of IR was confirmed after adjustment for gender, immunovirological status, exposure to D4T, BMI, HCV clearance at enrollment, elevated coffee consumption, and cirrhosis (Table 4) . Age was neither a independent significant correlate nor a confounder and was not included in the final model. A second model was built (model 2, Table 4 ) by removing cirrhosis from model 1, as it was collinear with low coffee consumption. In model 2, elevated coffee consumption was independently associated with lower risk of IR.
Sensitivity analyses confirmed the association with cannabis use (yes vs no) when using a HOMA-IR cutoff value of 3. 
DISCUSSION
This is the first longitudinal study to document the relationship between the reduced risk of IR and cannabis use in a population particularly concerned with IR risk. The results were robust, as they were confirmed in 3 sensitivity analyses; 1 of these analyses included patients with diabetes. Our results are consistent with those from previous research [12] and, in particular, with a recent cross-sectional study conducted in the US general population [11] . In our study, cannabis users were more likely to have a low BMI, which is in line with previous research [10] . As a high BMI is also associated with increased risk of diabetes, it was necessary to adjust for BMI in the final model in order to determine whether the relationship between cannabis use and IR could be confirmed. The associations we found among cannabis use, obesity, and reduced risk of IR are also consistent with results from animal models. When administered to obese rats, cannabis was associated with weight reduction and an increase in the weight of the pancreas, implying beta-cell protection [28] .
The mechanisms by which cannabinoids affect peripheral metabolism via type 1 and 2 cannabinoid receptors have been extensively studied [29] . Nevertheless, the causal link is not completely understood. Evidence is emerging that some nonpsychotropic plant cannabinoids, such as cannabidiol, can be used to retard beta-cell damage in type I diabetes [29] . For example, mice models suggest that rimonabant, the cannabinoid type 1 receptor antagonist, can improve insulin sensitivity and that this effect is mediated by adiponectin [30] . However, a recent study in adiponectin knockout mice showed that improvement of insulin sensitivity in obese mice on rimonabant is independent of adiponectin [31] . Another recent study by Muniyappa et al [32] shows that chronic cannabis use increases adipocyte IR without affecting glucose insulin sensitivity. It is therefore difficult to say whether or not the association found in our study is attributable to this adiponectin-mediated mechanism. Moreover, such a mechanism (ie, modification of adiponectin levels) has also been documented for coffee intake [33] . The association we found between elevated coffee consumption and reduced risk of IR is also consistent with a relationship found in the same cohort using cross-sectional enrollment data [22] and that found in a very recent study in a large cohort of health staff [34] . Previous studies have already shown that several combined effects of coffee components (chlorogenic acid, in particular) may have different consequences, including the regulation of hormones involved in satiety and insulin secretion [35] .
Individuals who presented with HIV viral replication were at lower risk of IR in our study, perhaps because this variable is a proxy of no or suboptimal exposure to antiretroviral treatment, not of virological failure. Among all antiretroviral agents tested, only exposure to stavudine (D4T) remained statistically significant in the final model, confirming previous results that showed that cumulative exposure to stavudine predicts IR [5] and diabetes [36] in HIV-infected individuals. As highlighted by Loko et al [6] , the mechanism that links exposure to specific antiretroviral agents, IR, and liver fibrosis is complex and is mediated by mitochondrial toxicity.
Some limitations of this study need to be acknowledged. First, the assessment of cannabis use was based on self-reports. Accordingly, social desirability bias may have resulted in underreporting of such behaviors. Second, there is no gold standard for the cutoff values for HOMA-IR, and we preferred to use those indicated for patients with no diabetes and genotype 1 [17, 19] in order to obtain a more sensitive measure of IR. However, the use of a more "specific" (higher) cutoff value and measurement of the outcome as a continuous variable in the sensitivity analyses confirmed the association between cannabis use and reduced IR risk. Third, the generalization of our findings may be limited by the exclusion of individuals who did not answer the self-administered questionnaire and who exhibited poorer immunological status than those included in the analysis. Nevertheless, because the French healthcare system guarantees free access to HIV and HCV care for all patients, the HEPAVIH cohort is likely to include a higher proportion of underprivileged populations than most clinical trials or other longitudinal studies carried out in countries where such access is not available.
There are several cannabis-based pharmacotherapies that do not rely on herbal marijuana and are used for specific indications (eg, symptoms relief in multiple sclerosis). The benefits of these products for patients concerned with increased risk of IR and diabetes need to be evaluated in clinical research and practice.
Notes
